Shire : Form 8.5 (EPT/NON-RI)

October 20, 2014 at 06:59 am

FORM 8.5 (EPT/NON-RI)

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader:	(GS) GOLDMAN, SACHS & CO.
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree	SHIRE PLC
(c) Name of the party to the offer with which exempt principal trader is connected:	SHIRE PLC
(d) Date position held/dealing undertaken:	17 October 2014
(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?	NO

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	5p ordinary and ADRs
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	5,937	0.00	248,817	0.04
(2) Derivatives (other than options):	75,588	0.01	75,588	0.01
(3) Options and agreements to purchase/sell:	0	0.00	0	0.00
TOTAL:	81,525	0.01	324,405	0.05

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other executive options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
ADR / (1.00 : 3.00)	Sale	100 (300)	179.1500 USD
ADR / (1.00 : 3.00)	Sale	45 (135)	179.1500 USD
ADR / (1.00 : 3.00)	Sale	219 (657)	179.1550 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.2000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.2200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.2600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.3900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.4900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.4900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.4950 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.5100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.5600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.5700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.6100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.6100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.6500 USD
ADR / (1.00 : 3.00)	Sale	99 (297)	179.6900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.6900 USD
ADR / (1.00 : 3.00)	Sale	1 (3)	179.6900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.7700 USD
ADR / (1.00 : 3.00)	Sale	98 (294)	179.7700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.8000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.8400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.8400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.8500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.8550 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.8600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.8600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.8950 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9250 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9550 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9550 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9600 USD
ADR / (1.00 : 3.00)	Sale	10 (30)	179.9700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9800 USD
ADR / (1.00 : 3.00)	Sale	29 (87)	179.9900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9900 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	179.9900 USD
ADR / (1.00 : 3.00)	Sale	6 (18)	179.9900 USD
ADR / (1.00 : 3.00)	Sale	58 (174)	179.9900 USD
ADR / (1.00 : 3.00)	Sale	15 (45)	179.9900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	179.9950 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.0200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.0500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.0600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.0800 USD
ADR / (1.00 : 3.00)	Sale	32 (96)	180.0800 USD
ADR / (1.00 : 3.00)	Sale	68 (204)	180.0800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.0950 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	180.1100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.1100 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	180.1100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.1300 USD
ADR / (1.00 : 3.00)	Sale	17 (51)	180.1400 USD
ADR / (1.00 : 3.00)	Sale	83 (249)	180.1400 USD
ADR / (1.00 : 3.00)	Sale	35 (105)	180.1500 USD
ADR / (1.00 : 3.00)	Sale	65 (195)	180.1500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.1700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.1700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.1800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.2250 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.2300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.2300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.3200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.4700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.4800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.4800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.5500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.5750 USD
ADR / (1.00 : 3.00)	Sale	33 (99)	180.5900 USD
ADR / (1.00 : 3.00)	Sale	11 (33)	180.5900 USD
ADR / (1.00 : 3.00)	Sale	33 (99)	180.5900 USD
ADR / (1.00 : 3.00)	Sale	23 (69)	180.5900 USD
ADR / (1.00 : 3.00)	Sale	33 (99)	180.6000 USD
ADR / (1.00 : 3.00)	Sale	67 (201)	180.6000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.6300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.6600 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	180.8300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.8300 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	180.8300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.8300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.8700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.8800 USD
ADR / (1.00 : 3.00)	Sale	71 (213)	180.9000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.9000 USD
ADR / (1.00 : 3.00)	Sale	99 (297)	180.9400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.9400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.9600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.9600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.9700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.9800 USD
ADR / (1.00 : 3.00)	Sale	38 (114)	180.9800 USD
ADR / (1.00 : 3.00)	Sale	33 (99)	180.9800 USD
ADR / (1.00 : 3.00)	Sale	67 (201)	180.9800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.9900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	180.9900 USD
ADR / (1.00 : 3.00)	Sale	1 (3)	181.0000 USD
ADR / (1.00 : 3.00)	Sale	33 (99)	181.0000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.0000 USD
ADR / (1.00 : 3.00)	Sale	33 (99)	181.0000 USD
ADR / (1.00 : 3.00)	Sale	33 (99)	181.0000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.0100 USD
ADR / (1.00 : 3.00)	Sale	9 (27)	181.0200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.0200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.0400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.0500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.0500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.0600 USD
ADR / (1.00 : 3.00)	Sale	33 (99)	181.0700 USD
ADR / (1.00 : 3.00)	Sale	66 (198)	181.0700 USD
ADR / (1.00 : 3.00)	Sale	1 (3)	181.0700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.0850 USD
ADR / (1.00 : 3.00)	Sale	41 (123)	181.1000 USD
ADR / (1.00 : 3.00)	Sale	55 (165)	181.1200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.1400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.1400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.1500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.1650 USD
ADR / (1.00 : 3.00)	Sale	56 (168)	181.2100 USD
ADR / (1.00 : 3.00)	Sale	44 (132)	181.2100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.2150 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.2400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.2400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.2800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.4000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.4400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.4600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.4600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.4900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5250 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5250 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5500 USD
ADR / (1.00 : 3.00)	Sale	86 (258)	181.5700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5700 USD
ADR / (1.00 : 3.00)	Sale	55 (165)	181.5800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5800 USD
ADR / (1.00 : 3.00)	Sale	45 (135)	181.5800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.5950 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.6400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.6450 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.6800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.6900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.6900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.7100 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	181.7200 USD
ADR / (1.00 : 3.00)	Sale	47 (141)	181.7200 USD
ADR / (1.00 : 3.00)	Sale	3 (9)	181.7200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.7300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.7300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.7400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.7800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.8100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.8150 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	181.8400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.8400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.8400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.8400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.8600 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	181.8600 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	181.8600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.8900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9150 USD
ADR / (1.00 : 3.00)	Sale	24 (72)	181.9200 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	181.9200 USD
ADR / (1.00 : 3.00)	Sale	26 (78)	181.9200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9350 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9400 USD
ADR / (1.00 : 3.00)	Sale	85 (255)	181.9500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9650 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9750 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9750 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9850 USD
ADR / (1.00 : 3.00)	Sale	64 (192)	181.9900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	181.9900 USD
ADR / (1.00 : 3.00)	Sale	36 (108)	181.9900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0000 USD
ADR / (1.00 : 3.00)	Sale	20 (60)	182.0000 USD
ADR / (1.00 : 3.00)	Sale	80 (240)	182.0000 USD
ADR / (1.00 : 3.00)	Sale	2 (6)	182.0000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0100 USD
ADR / (1.00 : 3.00)	Sale	6 (18)	182.0100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0500 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	182.0600 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	182.0600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0650 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.0700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1250 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1400 USD
ADR / (1.00 : 3.00)	Sale	56 (168)	182.1500 USD
ADR / (1.00 : 3.00)	Sale	44 (132)	182.1500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1550 USD
ADR / (1.00 : 3.00)	Sale	2 (6)	182.1600 USD
ADR / (1.00 : 3.00)	Sale	11 (33)	182.1600 USD
ADR / (1.00 : 3.00)	Sale	89 (267)	182.1600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1850 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.1900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.2000 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	182.2100 USD
ADR / (1.00 : 3.00)	Sale	43 (129)	182.2100 USD
ADR / (1.00 : 3.00)	Sale	7 (21)	182.2100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.2150 USD
ADR / (1.00 : 3.00)	Sale	45 (135)	182.2200 USD
ADR / (1.00 : 3.00)	Sale	43 (129)	182.2200 USD
ADR / (1.00 : 3.00)	Sale	55 (165)	182.2200 USD
ADR / (1.00 : 3.00)	Sale	48 (144)	182.2400 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	182.2500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.2500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.2700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.2750 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.2900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3450 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.3750 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.4100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.4100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.4200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.4300 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.4400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.4400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.4400 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.4500 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	182.4600 USD
ADR / (1.00 : 3.00)	Sale	50 (150)	182.4600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.4700 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.4900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.5000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.5100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.5100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.5200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.5500 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.6200 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.6800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.6800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.6800 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.7450 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.7650 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.8400 USD
ADR / (1.00 : 3.00)	Sale	28 (84)	182.9600 USD
ADR / (1.00 : 3.00)	Sale	72 (216)	182.9600 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	182.9900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	183.0000 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	183.0100 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	183.0900 USD
ADR / (1.00 : 3.00)	Sale	100 (300)	183.0900 USD

Class of relevant security	Purchases/sales	Total number of securities
ADR / (1.00 : 3.00)	Sales	25,415 (76,245)

(b) Derivatives transactions (other than options)

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

ADR / (1.00 : 3.00)

SWAP / (1.00 : 3.00)

Opening a long position

25,196 (75,588)

181.4961 USD

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercising

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

NONE

Is a Supplemental Form 8 (Open Positions) attached?

YES

Date of disclosure:	20 October 2014
Contact name:	Aadithya Rao and Yiannis Bardis
Telephone number:	+44(20) 7051 9046 / +44(20) 7774 7107

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website atwww.thetakeoverpanel.org.uk.

SUPPLEMENTAL FORM 8(OPEN POSITIONS)

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENT TO

PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

1. KEY INFORMATION

Identity of the person whose open positions are being disclosed:	(GS) GOLDMAN, SACHS & CO.
Name of offeror/offeree in relation to whose relevant securities disclosure relates:	SHIRE PLC

2. OPTIONS AND DERIVATIVES

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date
5p ordinary	Swap	Sold	10,653	0.0000	N/A	17/09/2015
5p ordinary	Swap	Sold	29,805	0.0000	N/A	17/09/2015
5p ordinary	Swap	Sold	35,130	0.0000	N/A	17/09/2015
5p ordinary	Swap	Purchased	75,588	0.0000	N/A	22/10/2015

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

It is not necessary to provide details on a Supplement form (Open Positions) with regard to contracts for differences ("CFD") or spread bets

The currency of all pieces and other monetary amounts should be stated.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

This information is provided by RNS

The company news service from the London Stock Exchange

ENDFEOMMBMTMBITBMI

distributed by

S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	18-12-21	RE
Asia M&A clocks second best on record, strength to persist despite trade troubles	18-12-20	RE
British shares falter as Fed, oil play Scrooge	18-12-20	RE
FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	18-12-19	RE
FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	18-12-18	RE
FTSE : down sharply as ASOS profit alert sparks wider retail selloff	18-12-17	RE
FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	18-12-07	RE
FTSE : falls as growth angst spreads	18-12-05	RE
Growth and trade nerves grind European shares down to two-week low	18-12-05	RE
Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	18-12-05	RE
Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	18-12-05	RE
Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	18-11-21	RE
Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	18-11-21	RE
Takeda Pharmaceutical : Shire takeover to bring $963 million fee bonanza	18-11-12	RE
FTSE : outperforms European peers as Brexit angst sinks sterling	18-11-12	RE
Takeda Pharmaceutical : sets vote date, aims to close $62 billion Shire deal January 8	18-11-12	RE
Takeda Pharmaceutical : sets vote date, aims to close $62 billion Shire deal on January 8	18-11-12	RE
Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources	18-11-09	RE
Exclusive: Takeda to win EU approval for $62 billion Shire deal - sources	18-11-09	RE
Takeda Pharmaceutical : CEO confident of investor backing for $62 billion Shire deal	18-11-05	RE
Takeda Pharmaceutical : hikes annual profit outlook by a third after second quarter profit jump	18-10-31	RE
Takeda Pharmaceutical : proposes sale of Shire drug to gain European approval	18-10-29	RE
Takeda Pharmaceutical : gets Japanese approval for $62 billion Shire purchase	18-10-18	RE
Bayer : Beset by copies, Roche gets sales boost from China	18-10-17	RE
FTSE : shrugs off Brexit impasse while Convatec and Superdry sink	18-10-15	RE

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+26.47%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.33%	352B
MERCK & CO., INC.	+19.35%	332B
ABBVIE INC.	+4.23%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.04%	145B

Shire

Equities

JE00B2QKY057

Pharmaceuticals

Shire : Form 8.5 (EPT/NON-RI)

Latest news about Shire

Chart Shire

Company Profile

Sector Other Pharmaceuticals